Objetivo Antibiotics resistance of pathogens is a major threat to public health and safety. The rapid spread of resistant strains increases the risk of epidemics. This issue also includes preparedness to deal with bio-terrorism. The objectives of the ET-PA project are to develop an open, generic platform to enable the development of new classes of protein-antibiotics. The key technology (REPPs) is based on a principle that is proprietary to one of the participating SMEs, consisting of rationally modified class II restriction enzymes (RE) fused to cell penetration peptide sequences (PP) that selectively allow microbial cell penetration. Introduction of a REPP system into pathogens would lead to effective cell killing. The REPP will be designed to inactivate major microbial pathogens, i.e. S. aureus, P. aeruginosa and C. Albicans. Addressing these ambitious objectives will require a Co-operative Research setup with complementing expertise and resources, coming both from high-tech SMEs and expert academic RTD partners. The ET-PA project will be divided into four work packages:1.Discovery -The design of a technology platform for the discovery of PP sequences for proper function in antibiotic REPP constructs.2.Characterization -extensive characterization of the biological activity of antibiotic REPP constructs.3.Technological platform - configuration of a semi-automatic and embedding technology platform that enables a coherent and unified approach for a rapid translation of REPP components into protein antibiotics.4.Management - to assure, consolidation and coordination of the ET-PA project, support and protection of Intellectual Property, and contacts to subsequently license the outcomes to a third-party end-user.The commitment and collective efforts of all participants is the best warranty for a success of the ET-PA project that will provide a technology platform to translate the most effective horizontal bacterial defence system into innovative medicine. Ámbito científico medical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomicsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistancenatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes Programa(s) FP6-SME - Horizontal research activities involving SMEs: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Tema(s) SME-1 - Co-operative Research (all areas of science and technology) Convocatoria de propuestas FP6-2003-SME-1 Consulte otros proyectos de esta convocatoria Régimen de financiación Data not available Coordinador ADRIACELL SRL. Aportación de la UE Sin datos Dirección S.S.14km163.5 TRIESTE Italia Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos Participantes (4) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo BIA SEPARATIONS D.O.O. Eslovenia Aportación de la UE Sin datos Dirección Teslova 30 LJUBLJANA Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos HECUS X-RAY SYSTEMS GMBH Austria Aportación de la UE Sin datos Dirección Moserhofgasse 15 GRAZ Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN Alemania Aportación de la UE Sin datos Dirección Sigmund-Freud-Strasse 25 BONN Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos UNIVERSITA DEGLI STUDI DI TRIESTE. Italia Aportación de la UE Sin datos Dirección Piazzale Europa 1 TRIESTE Ver en el mapa Enlaces Sitio web Opens in new window Coste total Sin datos
